The current pipeline features a diverse range of assets, including antibody drugs, small molecules, and ADCs targeting various cancers and autoimmune diseases from preclinical to Phase II.
We have also selected few commercial stage products markets in China open for licensing.
Interested in one of our innovative pipelines? Let's discuss your licensing opportunities in depth. Schedule a meeting with Unibest experts to explore how we can collaborate on bringing cutting-edge pharmaceuticals to global markets.
The transcription factor c-Myc has emerged as a critical target in oncology, given its aberrant expression in more than 70% of human cancers. Unibest presents a first-in-class small molecule glue targeting c-Myc open for NewCo.
In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104.
The transcription factor c-Myc has emerged as a critical target in oncology, given its aberrant expression in more than 70% of human cancers. Unibest presents a first-in-class small molecule glue targeting c-Myc open for NewCo.